The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
HIV “shock and kill” therapy: In need of revision
Abstract
The implementation of antiretroviral therapy 23 years ago has rendered HIV infection clinically manageable. However, the disease remains incurable, since it establishes latent proviral reservoirs, which in turn can stochastically begin reproducing viral particles throughout the patient's lifetime. Viral latency itself depends in large part on the silencing environment of the infected host cell, which can be chemically manipulated. "Shock and kill" therapy intends to reverse proviral quiescence by inducing transcription with pharmaceuticals and allowing a combination of antiretroviral therapy, host immune clearance and HIV-cytolysis to remove latently infected cells, leading to a complete cure. Over 160 compounds functioning as latency-reversing agents (LRAs) have been identified to date, but none of the candidates has yet led to a promising functional cure. Furthermore, fundamental bioinformatic and clinical research from the past decade has highlighted the complexity and highly heterogeneous nature of the proviral reservoirs, shedding doubt on the "shock and kill" concept. Alternative therapies such as the HIV transcription-inhibiting "block and lock" strategy are therefore being considered. In this review we describe the variety of existing classes of LRAs, discuss their current drawbacks and highlight the potential for combinatorial "shocktail" therapies for potent proviral reactivation. We also suggest investigating LRAs with lesser-known mechanisms of action, and examine the feasibility of "block and lock" therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Finzi, D., Blankson, J., Siliciano, J. D., Margolick, J. B., Chadwick, K., Pierson, T., Smith, K., Lisziewicz, J., Lori, F., Flexner, C., et al. (1999) · Nature Medicine · doi:10.1038/8394 · Cited by 2,119
NF-κB Directs Dynamic Super Enhancer Formation in Inflammation and Atherogenesis
Brown, J. D., Lin, C. Y., Duan, Q., Griffin, G., Federation, A. J., Paranal, R. M., Bair, S., Newton, G., Lichtman, A. H., Kung, A. L., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.08.024 · Cited by 614
Yeung, M. L., Bennasser, Y., Watashi, K., Le, S.-Y., Houzet, L., & Jeang, K.-T. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp707 · Cited by 244
Doyon, G., Zerbato, J., Mellors, J. W., & Sluis-Cremer, N. (2013) · AIDS · doi:10.1097/qad.0b013e3283570620 · Cited by 107
Zhao, F., Huang, W., Zhang, Z., Mao, L., Han, Y., Yan, J., & Lei, M. (2016) · Oncotarget · doi:10.18632/oncotarget.6783 · Cited by 77
Selective HDAC Inhibition for the Disruption of Latent HIV-1 Infection
Barton, K. M., Archin, N. M., Keedy, K. S., Espeseth, A. S., Zhang, Y.-L., Gale, J., Wagner, F. F., Holson, E. B., & Margolis, D. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102684 · Cited by 76
Cited by
Microglial Cells: The Main HIV-1 Reservoir in the Brain
Wallet, C., De Rovere, M., Van Assche, J., Daouad, F., De Wit, S., Gautier, V., Mallon, P. W. G., Marcello, A., Van Lint, C., Rohr, O., et al. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00362 · Cited by 368
GS-9822, a Preclinical LEDGIN Candidate, Displays a Block-and-Lock Phenotype in Cell Culture
Bruggemans, A., Vansant, G., Balakrishnan, M., Mitchell, M. L., Cai, R., Christ, F., & Debyser, Z. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02328-20 · Cited by 35
Janssens, J., De Wit, F., Parveen, N., & Debyser, Z. (2022) · mBio · doi:10.1128/mbio.00007-22 · Cited by 28
Dudek, A. M., Feist, W. N., Sasu, E. J., Luna, S. E., Ben-Efraim, K., Bak, R. O., Cepika, A.-M., & Porteus, M. H. (2024) · Cell Stem Cell · doi:10.1016/j.stem.2024.03.002 · Cited by 19
New latency-promoting agents for a block-and-lock functional cure strategy
Pellaers, E., Denis, A., & Debyser, Z. (2024) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000844 · Cited by 13
Metadata
- Authors
- Abner, E., & Jordan, A.
- Venue
- Antiviral Research
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 166
- Pages
- 19-34
- ISSN
- 0166-3542 (ISSN-L)
- OpenAlex
- W2923403959
- Cited by
- 170
- References
- 6
- FWCI
- 11.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HIV “shock and kill” therapy: In need of revision. https://app.cochat.ai/papers/10.1016/j.antiviral.2019.03.008
- The paper
- Abner, E., & Jordan, A. (2019). HIV “shock and kill” therapy: In need of revision. Antiviral Research. https://doi.org/10.1016/j.antiviral.2019.03.008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.